Skip to main content

Ani Pharmaceuticals Inc

ANIP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001023024

In the last 90 days, Ani Pharmaceuticals Inc insiders filed 0 open-market purchases and 10 sales; 307 institutions reported holding it in 13F filings for Q2 2026, worth $1.90B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Ani Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
10 filings
5 insiders, $1.94M in total
Insiders trading
5
Net value
−$1.94M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Ani Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Ani Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Lalwani NikhilPRESIDENT & CEO339,089Sep 16, 20267
Thoma JeanneDirector26,762Sep 14, 20262
Cook MeredithSR. VP, GENERAL COUNSEL & SEC.73,924Sep 14, 202615
Carey Stephen P.SVP & CFO171,843Sep 1, 202610
Gosebruch Henry ODirector6,662Aug 27, 20261
Gutwerg OriSVP, GENERICS75,534Aug 11, 20267
Haughey ThomasDirector38,878Jun 10, 20261
Tannenbaum Renee PDirector29,514Jun 10, 20262
Pera Antonio RDirector27,017Jun 10, 20261
Leonard Matthew JDirector11,221Jun 10, 20261
Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS38,271May 13, 20265
Walsh Patrick DDirector38,432May 13, 20263
Mutz ChristopherHEAD OF RARE DISEASE91,309Mar 13, 20267
Davis KristaSVP, CHIEF HR OFFICER51,946Mar 10, 20266
Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS101,056Mar 2, 20262
Gassert ChadSVP - CORP. DEV. & STRATEGY74,916Mar 2, 20264
Marken James G.SVP OPS & PROD DEV117,829Jun 11, 20240
Meridian Venture Partners II LP10% Owner1,819,259Aug 16, 20230
Brown Robert E. JR10% Owner1,819,259Aug 16, 20230
Meridian Venture Partners II, Co.10% Owner1,819,259Aug 16, 20230
Meridian Venture Partners II GP, L.P.10% Owner1,819,259Aug 16, 20230
Nash DavidDirector38,561May 24, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 15, 2024 (view filing)Apr 123 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$67.79−$16.9K−0.4%59.7K after10b5-1
Apr 17, 2024 (view filing)Apr 15-172 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−22.8K$65.91−$1.50M−2.7%809.9K after3 lots10b5-1
Apr 22, 2024 (view filing)Apr 18-194 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−27.2K$65.10−$1.77M−3.4%782.6K after2 lots10b5-1
May 3, 2024 (view filing)May 12 daysGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$66.62−$1.33M−7.9%233.2K after10b5-1
May 13, 2024 (view filing)May 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$67.69−$16.9K−0.4%59.5K after10b5-1
May 16, 2024 (view filing)May 142 daysLalwani NikhilPRESIDENT & CEOSSale−16.7K$66.10−$1.10M−4.2%377.5K after
May 17, 2024 (view filing)May 161 dayTannenbaum Renee PDirectorSSale−2.00K$63.87−$127.7K−9.9%18.2K after
May 17, 2024 (view filing)May 15-172 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−37.1K$64.37−$2.39M−4.7%745.5K after3 lots10b5-1
May 21, 2024 (view filing)May 201 dayShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−12.9K$61.81−$794.6K−1.7%732.6K after10b5-1
May 22, 2024 (view filing)May 211 dayMutz ChristopherHEAD OF RARE DISEASESSale−2.00K$61.61−$123.2K−2.3%83.3K after
Jun 4, 2024 (view filing)Jun 31 dayGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$64.41−$1.29M−8.6%213.2K after10b5-1
Jun 6, 2024 (view filing)Jun 42 daysCarey Stephen P.SVP & CFOSSale−5.00K$63.58−$317.9K−3.0%162.0K after
Jun 6, 2024 (view filing)Jun 51 dayGutwerg OriSVP, GENERICSSSale−2.98K$67.00−$200.0K−3.7%77.2K after
Jun 14, 2024 (view filing)Jun 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$63.80−$15.9K−0.4%59.2K after10b5-1
Jun 20, 2024 (view filing)Jun 17-203 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−30.0K$60.59−$1.82M−4.1%702.6K after3 lots10b5-1
Jun 24, 2024 (view filing)Jun 213 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−20.0K$58.90−$1.18M−2.8%682.6K after10b5-1
Jul 2, 2024 (view filing)Jul 11 dayGassert ChadSVP - CORP. DEV. & STRATEGYSSale−20.0K$63.44−$1.27M−9.4%193.2K after10b5-1
Jul 15, 2024 (view filing)Jul 123 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$64.91−$16.2K−0.4%59.0K after10b5-1
Jul 17, 2024 (view filing)Jul 15-172 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−47.3K$63.73−$3.01M−6.9%635.4K after3 lots10b5-1
Jul 19, 2024 (view filing)Jul 181 dayShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−2.74K$62.00−$170.1K−0.4%632.6K after10b5-1
Aug 14, 2024 (view filing)Aug 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$59.62−$14.9K−0.4%57.0K after10b5-1
Sep 16, 2024 (view filing)Sep 133 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$56.82−$14.2K−0.4%56.7K after10b5-1
Oct 15, 2024 (view filing)Oct 141 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$57.19−$14.3K−0.4%56.5K after10b5-1
Nov 14, 2024 (view filing)Nov 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$61.36−$15.3K−0.4%56.2K after10b5-1
Nov 18, 2024 (view filing)Nov 153 daysMutz ChristopherHEAD OF RARE DISEASESSale−6.50K$57.70−$375.1K−7.8%76.8K after
Nov 27, 2024 (view filing)Nov 261 dayLalwani NikhilPRESIDENT & CEOSSale−33.5K$57.99−$1.94M−8.3%370.4K after2 lots
Dec 12, 2024 (view filing)Dec 111 dayDavis KristaSVP, CHIEF HR OFFICERSSale−1.00K$60.00−$60.0K−2.0%49.1K after10b5-1
Dec 16, 2024 (view filing)Dec 133 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−250$56.24−$14.1K−0.4%56.0K after10b5-1
Dec 18, 2024 (view filing)Dec 171 dayCarey Stephen P.SVP & CFOSSale−7.50K$55.79−$418.4K−4.6%154.5K after
Jan 13, 2025 (view filing)Jan 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$53.92−$21.6K−0.7%55.6K after10b5-1
Feb 18, 2025 (view filing)Feb 135 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$59.54−$23.8K−0.5%83.5K after10b5-1
Feb 24, 2025 (view filing)Feb 213 daysDavis KristaSVP, CHIEF HR OFFICERSSale−1.00K$60.20−$60.2K−1.4%68.6K after10b5-1
Mar 7, 2025 (view filing)Mar 52 daysGutwerg OriSVP, GENERICSSSale−5.38K$60.00−$323.0K−5.4%94.1K after2 lots
Mar 10, 2025 (view filing)Mar 73 daysDavis KristaSVP, CHIEF HR OFFICERSSale−1.00K$60.86−$60.9K−1.5%66.5K after10b5-1
Mar 14, 2025 (view filing)Mar 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$63.33−$25.3K−0.5%80.5K after10b5-1
Mar 20, 2025 (view filing)Mar 191 dayDavis KristaSVP, CHIEF HR OFFICERSSale−1.87K$65.00−$121.3K−2.8%64.7K after10b5-1
Apr 14, 2025 (view filing)Apr 14Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$68.96−$27.6K−0.5%80.1K after10b5-1
May 13, 2025 (view filing)May 94 daysShanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPSSSale−700$76.83−$53.8K−0.1%631.9K after10b5-1
May 13, 2025 (view filing)May 13Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$62.20−$24.9K−0.5%79.7K after10b5-1
May 15, 2025 (view filing)May 141 dayMutz ChristopherHEAD OF RARE DISEASESSale−4.00K$60.45−$241.8K−3.6%107.3K after
May 16, 2025 (view filing)May 151 dayGutwerg OriSVP, GENERICSSSale−881$60.07−$52.9K−1.0%89.9K after
Jun 16, 2025 (view filing)Jun 133 daysCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$61.37−$24.5K−0.5%79.3K after10b5-1
Jul 14, 2025 (view filing)Jul 14Same dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$64.88−$26.0K−0.5%78.9K after10b5-1
Aug 14, 2025 (view filing)Aug 122 daysHaughey ThomasDirectorSSale−19.3K$85.93−$1.66M−34.6%36.5K after
Aug 14, 2025 (view filing)Aug 122 daysRowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDSSSale−4.97K$85.71−$426.4K−10.9%40.8K after
Aug 14, 2025 (view filing)Aug 122 daysCarey Stephen P.SVP & CFOSSale−50.0K$86.07−$4.30M−21.7%180.9K after
Aug 14, 2025 (view filing)Aug 122 daysLalwani NikhilPRESIDENT & CEOSSale−57.0K$85.93−$4.89M−12.2%411.2K after
Aug 14, 2025 (view filing)Aug 122 daysGutwerg OriSVP, GENERICSSSale−5.87K$86.53−$508.2K−6.5%84.0K after
Aug 14, 2025 (view filing)Aug 131 dayCook MeredithSR. VP, GENERAL COUNSEL & SEC.SSale−400$88.87−$35.5K−0.5%76.5K after10b5-1
Aug 18, 2025 (view filing)Aug 153 daysWalsh Patrick DDirectorSSale−9.00K$89.05−$801.5K−11.4%70.0K after